Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)
Study Number: 

PH 280315

Phase: 
3
Trial categories: 
Gastric (Stomach)
Esophageal
Immunotherapy
Antibody therapy
Checkpoint blockade
Principal Investigator: